200 related articles for article (PubMed ID: 20716806)
21. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
Panczyk M
World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
[TBL] [Abstract][Full Text] [Related]
22. High stromal nicotinamide N-methyltransferase (NNMT) indicates poor prognosis in colorectal cancer.
Song M; Li Y; Miao M; Zhang F; Yuan H; Cao F; Chang W; Shi H; Song C
Cancer Med; 2020 Mar; 9(6):2030-2038. PubMed ID: 31989785
[TBL] [Abstract][Full Text] [Related]
23. [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].
Cohen R; Cervera P; Svrcek M; Dumont C; Garcia ML; Chibaudel B; de Gramont A; Pocard M; Duval A; Fléjou JF; André T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S72-81. PubMed ID: 26118880
[TBL] [Abstract][Full Text] [Related]
24. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
25. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
26. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
27. Biomarker-guided therapy for colorectal cancer: strength in complexity.
Sveen A; Kopetz S; Lothe RA
Nat Rev Clin Oncol; 2020 Jan; 17(1):11-32. PubMed ID: 31289352
[TBL] [Abstract][Full Text] [Related]
28. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
Cappuzzo F; Finocchiaro G; Rossi E; Jänne PA; Carnaghi C; Calandri C; Bencardino K; Ligorio C; Ciardiello F; Pressiani T; Destro A; Roncalli M; Crino L; Franklin WA; Santoro A; Varella-Garcia M
Ann Oncol; 2008 Apr; 19(4):717-23. PubMed ID: 17974556
[TBL] [Abstract][Full Text] [Related]
29. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
30. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
[TBL] [Abstract][Full Text] [Related]
31. What can the molecular pathologist offer for optimal decision making?
Richman SD; Hutchins GG; Seymour MT; Quirke P
Ann Oncol; 2010 Oct; 21 Suppl 7():vii123-9. PubMed ID: 20943604
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
33. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.
Akkad J; Bochum S; Martens UM
Langenbecks Arch Surg; 2015 Feb; 400(2):129-43. PubMed ID: 25701352
[TBL] [Abstract][Full Text] [Related]
34. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
Corti G; Bartolini A; Crisafulli G; Novara L; Rospo G; Montone M; Negrino C; Mussolin B; Buscarino M; Isella C; Barault L; Siravegna G; Siena S; Marsoni S; Di Nicolantonio F; Medico E; Bardelli A
Clin Colorectal Cancer; 2019 Jun; 18(2):91-101.e3. PubMed ID: 30981604
[TBL] [Abstract][Full Text] [Related]
35. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.
Okugawa Y; Toiyama Y; Toden S; Mitoma H; Nagasaka T; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
Gut; 2017 Jan; 66(1):107-117. PubMed ID: 26475630
[TBL] [Abstract][Full Text] [Related]
37. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
38. Evolving notions on immune response in colorectal cancer and their implications for biomarker development.
Grizzi F; Basso G; Borroni EM; Cavalleri T; Bianchi P; Stifter S; Chiriva-Internati M; Malesci A; Laghi L
Inflamm Res; 2018 May; 67(5):375-389. PubMed ID: 29322204
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.
Fanale D; Castiglia M; Bazan V; Russo A
Adv Exp Med Biol; 2016; 937():207-28. PubMed ID: 27573902
[TBL] [Abstract][Full Text] [Related]
40. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
